EVO Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of -21.44% compared to Evotec SE's net margin of 15.91%. Evotec SE's return on equity of -15.99% beat BioNTech SE's return on equity of -2.35%.

Evotec SE has a consensus price target of $6.9761, signalling upside risk potential of 41.42%. On the other hand BioNTech SE has an analysts' consensus of $136.02 which suggests that it could grow by 13.15%. Given that Evotec SE has higher upside potential than BioNTech SE, analysts believe Evotec SE is more attractive than BioNTech SE.

Evotec SE has a beta of 1.441, which suggesting that the stock is 44.072% more volatile than S&P 500. In comparison BioNTech SE has a beta of 0.182, suggesting its less volatile than the S&P 500 by 81.764%.

Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.

Evotec SE quarterly revenues are $203.3M, which are smaller than BioNTech SE quarterly revenues of $1.4B. Evotec SE's net income of -$43.6M is lower than BioNTech SE's net income of $217.9M. Notably, Evotec SE's price-to-earnings ratio is -- while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.87x versus 8.78x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

Halozyme Therapeutics has a net margin of -21.44% compared to Evotec SE's net margin of 47.23%. Evotec SE's return on equity of -15.99% beat Halozyme Therapeutics's return on equity of 156.62%.

Evotec SE has a consensus price target of $6.9761, signalling upside risk potential of 41.42%. On the other hand Halozyme Therapeutics has an analysts' consensus of $64.13 which suggests that it could grow by 26.96%. Given that Evotec SE has higher upside potential than Halozyme Therapeutics, analysts believe Evotec SE is more attractive than Halozyme Therapeutics.

Evotec SE has a beta of 1.441, which suggesting that the stock is 44.072% more volatile than S&P 500. In comparison Halozyme Therapeutics has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.598%.

Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. Halozyme Therapeutics pays out -- of its earnings as a dividend.

Evotec SE quarterly revenues are $203.3M, which are smaller than Halozyme Therapeutics quarterly revenues of $290.1M. Evotec SE's net income of -$43.6M is lower than Halozyme Therapeutics's net income of $137M. Notably, Evotec SE's price-to-earnings ratio is -- while Halozyme Therapeutics's PE ratio is 16.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.87x versus 6.92x for Halozyme Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

InflaRx NV has a net margin of -21.44% compared to Evotec SE's net margin of -14092.9%. Evotec SE's return on equity of -15.99% beat InflaRx NV's return on equity of -61.55%.

Evotec SE has a consensus price target of $6.9761, signalling upside risk potential of 41.42%. On the other hand InflaRx NV has an analysts' consensus of -- which suggests that it could grow by 251.27%. Given that InflaRx NV has higher upside potential than Evotec SE, analysts believe InflaRx NV is more attractive than Evotec SE.

Evotec SE has a beta of 1.441, which suggesting that the stock is 44.072% more volatile than S&P 500. In comparison InflaRx NV has a beta of 1.657, suggesting its more volatile than the S&P 500 by 65.659%.

Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.

Evotec SE quarterly revenues are $203.3M, which are larger than InflaRx NV quarterly revenues of $136.2K. Evotec SE's net income of -$43.6M is lower than InflaRx NV's net income of -$19.2M. Notably, Evotec SE's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.87x versus 730.60x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.

Immatics NV has a net margin of -21.44% compared to Evotec SE's net margin of -16.95%. Evotec SE's return on equity of -15.99% beat Immatics NV's return on equity of -16.88%.

Evotec SE has a consensus price target of $6.9761, signalling upside risk potential of 41.42%. On the other hand Immatics NV has an analysts' consensus of $16.75 which suggests that it could grow by 130.08%. Given that Immatics NV has higher upside potential than Evotec SE, analysts believe Immatics NV is more attractive than Evotec SE.

Evotec SE has a beta of 1.441, which suggesting that the stock is 44.072% more volatile than S&P 500. In comparison Immatics NV has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.769%.

Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.

Evotec SE quarterly revenues are $203.3M, which are larger than Immatics NV quarterly revenues of $55.6M. Evotec SE's net income of -$43.6M is lower than Immatics NV's net income of -$9.4M. Notably, Evotec SE's price-to-earnings ratio is -- while Immatics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.87x versus 5.84x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.